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Assessingmolecularpersistentorminimalresidualdisease(PD/MRD)inchildhoodBurkittlymphoma(BL)ischallengingbecause
access to original tumor is usually needed to design patient-speciﬁc primers (PSPs). Because BL is characterized by rearranged
immunoglobulin heavy chain (IgVH)g e n e s ,I g V H primer pools from IgVH1–IgVH7 regions were tested to detect PD/MRD, thus
eliminating the need for original tumor. The focus of the current study was to assess the feasibility of using IgVH primer pools
to detect disease in clinical specimens. Fourteen children diagnosed with B-NHL had follow-up repository specimens available
to assess PD/MRD. Of the 14 patients, 12 were PD/MRD negative after 2 months of therapy and remained in remission at the
end of therapy; 2/14 patients were PD/MRD positive at 2-3 months and later relapsed. PSP-based assays from these 14 patients
showed 100% concordance with the current assay. This feasibility study warrants further investigation to assess PD/MRD using
IgVH primer pools, which could have clinical signiﬁcance as a real-time assessment tool to monitor pediatric BL and possibly other
B-cell non-Hodgkin lymphoma therapy.
Copyright © 2009 Melissa Agsalda et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The prognosis for children diagnosed with Burkitt lym-
phoma (BL) has improved dramatically over the last decade;
however a signiﬁcant percentage (30–40%) of children
with advanced disease remain unresponsive to or relapse
during therapy, particularly those with B-cell non-Hodgkin
lymphoma (NHL) [1–3]. Because the prognosis for children
who relapse during therapy is dismal, with an estimated
2-year overall survival of 10–30%, improvements in early
detection of disease may improve their overall disease-free
survival [2]. In such cases, identifying persistent disease or
minimal residual disease (PD/MRD) could be important if
the paradigm of early intervention when PD/MRD is found
can be translated from other pediatric cancers such as acute
lymphoblastic leukemia [4].
Malignant BL cells are usually characterized with
immunoglobulin heavy chain variable region (IgVH)g e n e
rearrangements. The IgVH is formed during normal B-cell
ontogeny by an ordered process of Ig gene rearrangement
through assembling distinct variable (V), diversity (D), and
joining (J) gene segments known as VDJ recombination
[5]. A single VH gene is chosen from the available VH
repertoire consisting of >50 potentially functional genes that
are grouped into 7 structurally related families (VH1–7)[ 6].
Rearrangements of VH genes can be exploited by analyzing
the VH1–7 regions using polymerase chain reaction (PCR).
We and others previously used this molecular ﬁngerprint
from NHL primary diagnostic tissue to detect PD/MRD
in followup specimens [7–9]. However, as a clinical tool,
identifying patient-speciﬁc primers (PSPs) designed from
primary diagnostic tissue is labor-intensive and may not be
applicable for real-time applications [7]. When faced with
limitedamountoftissueatthetimeofdiagnosis,particularly
from children, there may not be enough tissue available to
design PSP if PD/MRD studies are to be tested [10–12].
The current study hypothesizes that detection of PD/MRD
in BL cases may be accomplished by more eﬃcient means
and not require primary diagnostic tissue to design unique
PSP. Instead, PD/MRD assessment could be achieved with2 Advances in Hematology
primer pools made up of IgVH oligomers from respective
VH1 to VH7 families. Thus a strategy was designed to detect
PD/MRDwithconsensusprimerpoolsbyreal-timePCR[7].
We report data using the primer pool method and compare
results previously reported by our lab using PSPs [13].
2.Methods and Materials
The study focused on the feasibility of using pools of
oligomers comprised of primers from the seven VH regions
(VH1–7) to amplify a clonal immunoglobulin heavy chain
rearrangement that would be characteristic of BL cells by
real-time PCR. The study, which was approved by the Insti-
tutional Review Board, analyzed repository specimens and
compared against previous results in which the specimens
were characterized using PSPs.
2.1. Patients and Specimens. Fourteen children with Burkitt
lymphoma(BL)andknownclinicaloutcomeshadspecimens
available which were previously analyzed using PSP [7]. The
diagnoses and staging were conﬁrmed through a central
review mechanism [7]. DNA from primary diagnostic tumor
tissues and staging/followup specimens (peripheral blood
mononuclear cells, PBMCs; bone marrow aspirate, BMA;
cerebrospinal ﬂuid, CSF) were available from paraﬃn-
embedded diagnostic tissue, unstained peripheral blood
smears/bone marrow slides, and CSF cell pellets; see Table 1
[7]. DNA was assessed by ultraviolet spectrophotometry and
by ampliﬁcation with beta-globin primers, which showed
adequate quantity and quality for PCR [13]. Specimens
were from entry (diagnostic) and followup time points
(1-month and 2-month postinduction chemotherapy); see
Table 1. From the primary diagnostic tumor tissue, PSPs
were designed and used to assess PD/MRD on followup
specimens as previously reported [7].
2.2.Real-TimePCRUsingVH1–VH7 PrimerPoolsandSensitiv-
ity Assessment. Groups of 5 -primers from the FR1 region of
thevariableIgHregions, VH1–VH7 (OperonBiotechnologies,
Inc, Huntsville, AL, USA) were combined to form primer
pools:VH1,V H2,V H3,V H4,V H5,V H6,andV H7 (Table 2)iden-
tiﬁed through VBASE23 (http://vbase.mrc-cpe.cam.ac.uk/)
[14]. Primers were designed from the FR1 region because
of future plans to use the assay on DNA extracted from
fresh or unstained slides of PBMC, BMA, and CSF. The two
consensus 3 -primers were: LJH and VLJH [7]. Seminested
real-time PCR was performed in triplicate using an iCycler
(BioRadLaboratories,Hercules,CA,USA),andStepOnePlus
(Applied Biosystems, Foster City, CA, USA). The PCR
parameters were optimized initially with DNA from a B-
cell NHL cell line, Ramos (ATCC, Manassas, VA, USA) by
diluting control human PBMC DNA as noted below with
negative and positive controls consisting of peripheral blood
mononuclearcells(PBMCs),water,andBLtumorDNA.The
primer pool concentrations of 10pmol were found to be
optimal with the PCR mix of 2x iQ SYBR Green Supermix
(Biorad Laboratories, Hercules, CA, USA), 10pmol 5 -IgVH
primer pools and 10pmol 3 -primer (LJH) and parameters:
95◦C/3minutes;35cycles95◦C/10seconds,60◦C/30seconds;
72◦C/3minutes; ﬁnal extension of 72◦C/3minutes. PCR
products were puriﬁed using ExoSAP-it (USB Corp, Cleve-
land, Ohio, USA), and recovered in 10μL. An aliquot of
1μLwasusedforsecond-roundPCRwith10pmol5 -primer
pools and 10pmol 3 -primer (VLJH). Following threshold-
dependent cycling, melting was performed from 60 to 95◦C
at either 0.5◦C/s or 0.1◦C/s melt rates with a smooth curve
setting averaging 1 point with minor modiﬁcations of a
previously described strategy to identify unique ampliﬁed
products [9, 15]. Melt curves were plotted as the negative
ﬁrstderivativeofdecreaseinﬂuorescenceversustemperature
(−dF/−dT). Polyclonal products of diﬀerent lengths would
melt at diﬀerent temperatures and displayed as broad peaks.
A wide melt curve peak deﬁned as the width at half height ≥
peak height was considered a negative result modiﬁed from
previous reports due to diﬀerent primers and compensations
made in the current real-time methodology versus the plate
reader assay [16, 17]. Thus a positive (peak height ≥ width
at half height); negative (peak height ≤ width at half height)
or equivocal (multiple peaks) determination was established
f o re a c hm e l tc u r v e ,( Figure 1) with veriﬁcation by resolving
the ampliﬁed products on agarose gels and sequencing, if
appropriate. Diﬀerentiation by melt-curve analysis led to
distinct melt temperatures for distinct ampliﬁed products if
a unique VH region is ampliﬁed and represented as a sharp
peak [18, 19]. Following PCR, samples were subjected to two
melt runs, with melt rates of either 0.1 or 0.5◦C/s if melt
peaks could not be distinguished [20]. As noted by others,
increasing the melt rate can increase the size of the melt
peaks due to a more rapid loss of ﬂuorescence, facilitating
morereliabledetectionofweakeramplicons[20].Sharpmelt
peaks corresponded to monoclonal bands while widened
or ﬂat melt curves suggested polyclonal or no clonal DNA,
Figures 1(b) and 1(c). If a melt curve suggested polyclonality,
PCR products were puriﬁed and sequenced. For the current
study, polyclonality determined by the sequence data was
interpreted as negative for MRD/PD.
An algorithm was established to screen for VH family
usage. In this study, each primary tumor tissue DNA was
subjected to each of the following combinations of primer
pools: VH1 &V H2;V H3 &V H4;V H5,V H6,&V H7. The strategy
allowedforcombinationsofVH primerstobeusedtoscr een-
inorscreen-outinvolvementofvariableregions.Ifparticular
primer pools were positive, then individual VH primers were
used to individually retest the tumor tissue DNA to identify
thevariableregioninvolved.ThespeciﬁcVH primerwasthen
used to assess PD/MRD on sequential specimens from the
same patient. Sensitivity of the assay was determined by two
methodsusingcelllineDNAandBLtumorDNA.DNAfrom
the B-cell NHL Ramos cell line and control human PBMC
were combined in various dilutions (DNA equivalent of 1
Ramos cell to 102,1 0 3,1 0 5,1 0 7,1 0 8,a n d1 0 9 PBMC DNA)
to test the IgVH primer pools [21]. Dilutions of DNA from
tumorDNAwerepreparedwithcontrolhumanPBMCtothe
DNA equivalent of 1 malignant cell to 103,1 0 5,1 0 6,1 0 8,a n d
109 PBMC DNA. Each dilution was then assayed using VH4
primer, which was a characteristic of that particular tumor
specimen.Advances in Hematology 3
Table 1: Persistent or minimal residual disease assessment using real-time and PSP assays.
Case (Dx) Real-time results/PSP results & clinical status∗
Entry 1 Mo 2 Mo 3-4 Mo Clinical status
NHL-1 (BL) Tissue (+/PSP) CR (End of Rx))
Blood (+/+) Blood (−/−) Blood (+/+) Blood (−/−)
NHL-2 (BL) Tissue (+/PSP) CR (End of Rx)
Blood (+/+) Blood (+/+) Blood (−/−)
BMA (+/+)
NHL-3 (BL) Tissue (+/PSP) Dead (Infection; 3 mo)
Blood (+/+) Blood (+/+)
BMA (+/+) BMA (−/−)
NHL-4 (BL) Tissue (+/PSP) CR ( End of Rx )
Blood (+/+) Blood (+/+) Blood (−/−)
NHL-5 (BL) Tissue (+/PSP) BMA relapse (6 mo)
Blood (+/+) Blood (−/−)
BMA (+/+) BMA (+/+)
NHL-6 (BL) Tissue (+/PSP) CR ( End of Rx )
BMA (+/+) BMA (−/−)
NHL-7 (BL) Tissue (+/PSP) BMA relapse (3 mo)
BMA (+/+) BMA (+/+)
NHL-8 (BL) Tissue (+/PSP)
Blood (+/+) Blood (−/−) Blood (−/−)C R ( E n d o f R x )
NHL-9 (BL)
Tissue (+/PSP)
Blood (+/+) Blood (+/+) Blood (−/−)C R ( E n d o f R x )
CSF (+/+) CSF (=/=)
NHL-10 (BL) Tissue (+/PSP)
Blood (+/+) Blood (−/−)C R ( E n d o f R x )
NHL-11 (BL) Tissue (+/PSP)
Blood (+/+) Blood (+/+) Blood (+/+) Blood (−/−)C R ( E n d o f R x )
NHL-12 (BL)
Tissue (+/PSP)
Blood (+/+) Blood (+/+) Blood (−/−)C R ( E n d o f R x )
BMA (Equiv) BMA (+/+) BMA (−/−)
CSF (+/+)
NHL-13 (BL)
Tissue (+/PSP)
Blood (+/+) Blood (=/=) Blood (=/=)
BMA (+/+) BMA(−/−)C R ( E n d o f R x )
CSF(−/−)
NHL-14 (BL)
Tissue (+/PSP)
Blood (+/+) Blood (−/−) Blood (−/−)C R ( E n d o f R x )
BMA (+/+)
∗Specimens were not available from some time points; Dx: diagnosis; BL: Burkitt lymphoma; BMA: bone marrow aspirate; real-time results/patient-speciﬁc
primer (PSPs) results: Positive (+), Negative (−), or Equivocal (=) for each assay result; CR: complete remission; End of Rx: End of therapy.
3. Results
3.1. Real-Time PCR Using VH1–VH7 Primer Pools and Sensi-
tivity Assessment. Dilutions of DNA from the control Ramos
cell line were assayed using the IgVH primer pools [22]. Melt
curve analysis of each reaction was plotted as the negative
ﬁrst derivative of decrease in ﬂuorescence with respect to
temperature (−dF/dT) and interpreted: Positive (distinct
peak with minimal or no shoulder); Negative (broad peak);
or Equivocal (multiple peaks with signiﬁcant shoulder);
see Figure 1. The dilution experiments demonstrated that
Ramos cells could be detected on the order of 1 in 105 to 1 in
106 PBMC. Using patient tumor DNA, the sensitivity of the
assay could detect malignant cells as low as 1 in 105 PBMC
(Figure 2).
PD/MRD assays were performed on clinical specimens
fromthe14subjectsinwhichprimarydiagnostictissueswere
available. The results were compared to the analyses from
the PSP method and found 100% concordance in that when
PD/MRD was positive via PSP method, the same result was4 Advances in Hematology
Table 2: Primers sequences.
Primer Sequence (5 –3 )
VH1a CAG GT(GT) CAG CTG GTG CAG
VH1b CAG GTC CAG CTT GTG CAG
VH1c (GC)AG GTC CAG CTG GTA CAG
VH1d CA(AG) ATG CAG CTG GTG CAG
VH2a CAG ATC ACC TTG AAG GAG
VH2b CAG GTC ACC TTG A(AG)G GAG
VH3a GA(AG) GTG CAG CTG GTG GAG
VH3b CAG GTG CAG CTG GTG GAG
VH3c GAG GTG CAG CTG TTG GAG
VH4a CAG (CG)TG CAG CTG CAG GAG
VH4b CAG (CG)TG CAG CTG CAG GAG
VH5a GA(AG) GTG CAG CTG GTG CAG
VH6a CAG GTA CAG CTG CAG CAG
VH7a CAG GT(CG) CAG CTG GTG CAA
LJH TGA GGA GAC GGT GAC C
VLJH GTG ACC AGG GNC CTT GGC CCC AG
B-globin (forward) GAA GAG CCA AGG ACA GGT AC
B-globin (reverse) CAA CTT CAT CCA CGT TCA CC
obtained using IgVH primer pools (Table 1)[ 7]. The ampli-
ﬁed products from the positive PD/MRD specimens were
sequenced, conﬁrming the monoclonality of the specimens.
Patients, NHL-5 and NHL-7, continued to have PD/
MRD in followup BMA specimens 2 months after starting
chemotherapy, and subsequently developed clinically
detectable relapse at 6 months and 3 months, respectively.
The ampliﬁed products from the BMA from these two
subjects were puriﬁed and sequenced, which conﬁrmed the
same clone as the original primary diagnostic tumor. The
other 12 cases demonstrated clearance of their followup
blood and/or bone marrow specimens and at the end of
therapy, remained in clinical remission. While no followup
specimens were available from patients NHL-5 and NHL-7,
the specimens which were positive for PD/MRD did not
have evidence of disease by standard microscopic pathology.
To determine the utility of the methodology in assessing
PD/MRDinspecimenswhenprimarydiagnostictissueswere
not available, staging (Entry) specimens from each of the
cases were assayed using IgVH primer pools using the same
strategy noted above. Each subject had staging specimens
which were positive for PD/MRD by a primer pool (Table 1).
This was important to verify, to validate the use of the strat-
egy in cases in which primary tumor tissue was not available.
4. Discussion
The current study was designed to assess PD/MRD on
followup specimens from pediatric B-NHL cases regardless
of whether primary diagnostic tissue was available from the
time of diagnosis. We hypothesized that PD/MRD could be
screened in specimens using primer pools made up of IgVH
oligomers from respective VH1 to VH7 families. The method
was compared to a previous study, which used the PSP-
basedassay,and theresultsdemonstrated100% concordance
[7]. Sequencing of the ampliﬁed products from primary
diagnostic tumor DNA conﬁrmed the results from the VH
oligomer ampliﬁed product demonstrating that monoclonal
results were represented by both methods.
The use of IgVH primer pools to screen for PD/MRD
in clinical specimens was shown to have potential and
feasibility. The current study is limited by the number of
subjects and specimens available; however, as a feasibility
study, the data support future consideration of the tool to
determine the clinical signiﬁcance of PD/MRD in pediatric
BL and possibly B-cell NHL therapy trials. A potential
limitation of the approach describe in this paper is that
the BL clone needs to have rearrangement of an IgH gene
[23]. Thus in BL cases involving immunoglobulin light
chain rearrangements, the primer pools will need to be
redesigned [23, 24]. There is precedence for potential utility
of real-time assessment of PD/MRD. PCR-based MRD assays
have been tested clinically in childhood acute lymphoblastic
leukemia (ALL) by targeting IgH gene rearrangements with
sensitivities on the order of one leukemic cell in 104–106
normal cells. Rapid reduction of MRD following induction
therapy was associated with a 3-year relapse rate less than
5%, while children with detectable MRD had a 3-year
relapse rate of 23%–75% [25]. In ALL, MRD was the most
powerfulprognosticfactorofoutcome,independentofother
risk factors (age, leukocyte count, cytogenetic abnormalities,
prednisone response), with similar results in children under-
going BM transplantation [26, 27]. To date, translating the
utility of MRD assessment in ALL to pediatric lymphoma
has been challenging, in part due to access to primary
diagnostic tissue in order to identify PSPs as a marker to be
used to assess followup specimens. Other challenges include
presence or absence of cytogenetic abnormalities such as
13q− and 7q+, which could be useful for prognosis, but
there remains a lack of consistent cytogenetic abnormalities
other than c-myc in childhood NHL for use in FISH or PCR
[28]. Thus, the current study could potentially be applicable
in assessing PD/MRD through IgVH oligomer pools in a
PCR assay that does not rely on primary diagnostic tissue
for a speciﬁc tumor marker. However there are currently
no universally accepted or recognized standard methods
to assess PD/MRD in pediatric BL for which to compare.
Because the current study is preliminary, emphasis should
be placed on the fact that the current assay cannot substitute
for the use of PSP-based assay and in the absence of primary
diagnostic tissue until further studies are completed.
Other investigators have studied the IgVH region in NHL
and found preferential VH gene usage with VH3 and VH4
families [8]. For the current study, we screened the primary
diagnostic specimens for all of the VH gene families (VH1 to
VH7) with the VH primer sets and found that, for the limited
number of cases, the majority included VH3 or VH4 families.
The data suggest that the PCR assay using IgVH primer pools
is able to identify B-NHL DNA in clinical specimens, with
the limitations as noted above. Clinical translational studies
withlargernumber of patients are needed to assessthe utility
of this assay to detect PD/MRD and determine the clinical
signiﬁcance. If the assay is validated in larger studies, one
of the potential advantages of the tool would be the ease ofAdvances in Hematology 5
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Figure 1: Examples of melt curve analyses with corresponding ethidium-stained ampliﬁed products. Melt curves displayed as −dF/dT plots:
(a) deﬁned peak with minimal to no shoulder indicates a positive MRD result; (b) a broad peak indicates a negative result; (c) a deﬁned
peak with signiﬁcant shoulders indicates equivocal results. Representative 2.0% agarose gels are at the left of each of graph. Melt curves of
negative controls: (d) PBMC from normal healthy individual shows a broad undeﬁned peak; (e) water (no template) shows no peak; (f) melt
curve assessment of PCR products: melt curve peak shift disparities are noted between diagnostic and followup specimens, consistent with
possible diﬀerent clonal diﬀerentiation over time.
Tumor PBMC 
103 105 106 108 109
Figure 2: MRD sensitivity with patient primary tumor DNA. Primary diagnostic tumor DNA (100% inﬁltrated with malignant cells) was
diluted with PBMC DNA to represent the equivalent of 1 malignant cell in 103,1 0 5,1 0 7,1 0 8,a n d1 0 9 PBMC. Each representative melt curve
has a distinct peak corresponding to tumor DNA or PBMC DNA, which are designated by the respective arrows.6 Advances in Hematology
assessing PD/MRD without the need of primary diagnostic
tissue.
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